GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Pharming Group N.V.
Pharming Group is a biopharmaceutical company specializing in the treatment of rare genetic diseases. Its share price is primarily driven by sales of its key drug, Ruconest. The chart reflects both commercial success and competitive risks.
Share prices of companies in the market segment - Pharma immune
Pharming is a biopharmaceutical company focused on treating rare genetic diseases. Its core segment is drugs for the treatment of hereditary angioedema. We classify it as part of the Pharma-immune sector, and the chart below reflects the dynamics of this entire niche industry.
Broad Market Index - GURU.Markets
Pharming Group is a Dutch biopharmaceutical company that develops and markets drugs to treat rare genetic diseases. As a component of the GURU.Markets index, it represents the orphan disease sector. The chart below shows the US market. See how Pharming shares compare to the US market.
Change in the price of a company, segment, and market as a whole per day
PHAR - Daily change in the company's share price Pharming Group N.V.
Price fluctuations at Pharming Group, a biopharmaceutical company, reflect the dynamics of the orphan drug market. Change_co demonstrates sensitivity to sales of its key product. This metric is an important component of formulas on System.GURU.Markets that assess volatility in the orphan drug sector.
Daily change in the price of a set of shares in a market segment - Pharma immune
Pharming Group N.V. is a biotech company. This chart demonstrates the extreme volatility of the sector. Comparison with PHAR, which focuses on rare disease treatments, helps to assess it as a high-risk, clinical-data-dependent asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Pharming is a biopharmaceutical company specializing in drugs for rare diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Pharming's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Pharming Group N.V.
Pharming is a biopharmaceutical company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Annual dynamics of market capitalization of the market segment - Pharma immune
Pharming Group N.V. is a biopharmaceutical company specializing in developing drugs for rare diseases. Its success depends on the commercialization of its approved drug. The chart shows how its niche strategy and portfolio expansion efforts influence its performance in the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Pharming is a biopharmaceutical company whose stock performance is driven by sales success of its drugs for rare diseases and progress in research. The company's business is not dependent on economic cycles. This chart reflects biotech events, not macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Pharming Group N.V.
Pharming, a biopharmaceutical company specializing in the treatment of rare genetic diseases. The monthly fluctuations on the chart reflect the sales dynamics of its flagship drug and news about clinical trials of new developments.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Biopharmaceutical companies specializing in rare diseases are valued based on the commercial success of their unique drugs. The performance of this niche sector, reflected in the chart, demonstrates investor confidence in business models built on orphan drugs, such as those developed by Pharming Group.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Pharming Group develops drugs for the treatment of rare diseases. The company's shares are driven by news about clinical trials and sales of its key drug. Their performance has little correlation with overall economic cycles.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Pharming Group N.V.
Shares of Pharming Group, a biopharmaceutical company specializing in rare diseases, react weekly to clinical and commercial news. Sales data for its key drug, as well as trial results for new indications, drive significant price movements.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Pharming Group shares, like those of the entire rare disease biotech sector, are moving in response to overall investor sentiment and regulatory news. These factors create general volatility for everyone. The chart will show how the company fares in this risky but promising field.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Pharming Group shares, like many biotechs, often move independently of the broader market. Their weekly performance is driven by clinical trial news, not macroeconomics. The chart will show moments when the company's shares completely defied the overall market trend.
Market capitalization of the company, segment and market as a whole
PHAR - Market capitalization of the company Pharming Group N.V.
The Pharming Group market capitalization chart is a financial valuation of a biotech company specializing in the treatment of rare hereditary diseases. It reflects the commercial success of its drug, Ruconest. Its dynamics tell the story of how a successful niche product can become the basis for further research and expansion of a development portfolio.
PHAR - Share of the company's market capitalization Pharming Group N.V. within the market segment - Pharma immune
Pharming Group is a Dutch biopharmaceutical company producing a drug for the treatment of a rare genetic disorder, hereditary angioedema. Its market share reflects its leadership in this niche. The chart shows how well its rabbit milk protein-based drug dominates its market.
Market capitalization of the market segment - Pharma immune
Pharming Group develops drugs to treat rare genetic diseases. The chart below shows the overall market capitalization of the immunopharmaceuticals sector. It reflects how science is finding solutions for diseases previously considered incurable. Pharming plays a vital role in this quest.
Market capitalization of all companies included in a broad market index - GURU.Markets
The biotechnologies visible in the chart treat rare diseases. Pharming Group produces a drug for the treatment of hereditary angioedema. Its market capitalization is based on the success of this niche but vital product and the development of new drugs for rare diseases.
Book value capitalization of the company, segment and market as a whole
PHAR - Book value capitalization of the company Pharming Group N.V.
For Pharming Group, this chart represents the material base for producing drugs for rare diseases. The increase in book value reflects the value of its biotech production facilities, where a drug for the treatment of hereditary angioedema is produced using transgenic animals.
PHAR - Share of the company's book capitalization Pharming Group N.V. within the market segment - Pharma immune
Pharming Group, a biotechnology company, controls unique production assets. Its stake in the sector is in facilities for producing recombinant proteins from the milk of transgenic rabbits. This specialized and complex physical infrastructure is the foundation of its business.
Market segment balance sheet capitalization - Pharma immune
Pharming Group is a biopharmaceutical company. Pharmaceuticals, as the chart shows, are capital-intensive. Pharming is a vertically integrated player. It owns the technology and manufacturing facilities for creating drugs based on recombinant proteins.
Book value of all companies included in the broad market index - GURU.Markets
Pharming Group N.V. is a biopharmaceutical company specializing in the treatment of rare genetic diseases. Its book value comes from the production capacity for its drug Ruconest and capital invested in the development of new treatments.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Pharming Group N.V.
Pharming Group is a biopharmaceutical company. Its production asset premium reflects the value of its commercial product for the treatment of a rare disease and its pipeline of developments that can support future growth.
Market to book capitalization ratio in a market segment - Pharma immune
Pharming Group develops drugs for rare diseases. Its flagship product generates its primary revenue. The chart shows how the market values this drug and the potential of the company's other developments. A high value indicates investor confidence in its scientific platform beyond the value of its tangible assets.
Market to book capitalization ratio for the market as a whole
Pharming Group is a biopharmaceutical company specializing in developing treatments for rare genetic diseases. This chart reflects the average market valuation of the company. Its valuation is based on the success of its commercial product and the potential of other drugs in its pipeline.
Debts of the company, segment and market as a whole
PHAR - Company debts Pharming Group N.V.
Pharming Group is a biopharmaceutical company developing drugs for rare diseases. The process from research to market launch takes years and requires hundreds of millions of dollars. Debt financing can be part of a strategy to ensure the continuity of clinical trials and prepare for the commercial launch of innovative products.
Market segment debts - Pharma immune
Pharming Group is a biopharmaceutical company specializing in rare diseases. Having a successful product on the market generates cash flow, but long-term growth requires investing in R&D and new drugs. This chart shows how the company balances profit reinvestment with the use of debt to expand its portfolio.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Pharming Group N.V.
Pharming Group develops drugs to treat rare diseases. This chart shows how the biopharmaceutical company balances equity and debt. While debt may be normal with an existing product, increasing it requires attention, as R&D setbacks or the emergence of competitors could undermine the company's ability to service it.
Market segment debt to market segment book capitalization - Pharma immune
Pharming Group develops drugs to treat rare genetic diseases. Biopharmaceuticals is one of the most capital-intensive industries, with a long and expensive path from lab to market. This chart reflects the overall debt burden in the sector, allowing one to assess how typical Pharming's financial strategy for raising funds for research and development is.
Debt to book value of all companies in the market
Pharming Group N.V. is a biopharmaceutical company developing drugs for rare diseases. The process from research to market is lengthy and expensive. This chart provides an overview of the company's overall cost of capital, allowing one to assess how the company finances its expensive clinical trials and how its debt policy compares to the high-risk nature of its business.
P/E of the company, segment and market as a whole
P/E - Pharming Group N.V.
This chart shows the valuation of Pharming Group, a biopharmaceutical company focused on rare diseases. A high P/E is the norm for this sector. This is driven by the high cost of orphan drugs and the lack of competition, which provides the company with high profitability and predictable demand.
P/E of the market segment - Pharma immune
Pharming Group is a Dutch biopharmaceutical company that produces Ruconest, a drug for the treatment of hereditary angioedema, a rare genetic disorder. This chart shows the average valuation for the biotech sector. It helps assess the market perception of the company's lead drug and its R&D efforts.
P/E of the market as a whole
Pharming Group is a biopharmaceutical company specializing in developing treatments for rare genetic diseases. Its valuation depends on the commercial success of its lead drug and the development of new programs. General market sentiment, reflected in this chart, has little impact on its business, which is driven by the specifics of the orphan disease market.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Pharming Group N.V.
Pharming Group is a biopharmaceutical company developing drugs to treat rare genetic diseases. Their flagship product is designed to treat hereditary angioedema. This chart reflects analysts' expectations for future sales growth of existing drugs and the success of new developments in clinical trials.
%20P%2FE%20Pharming%20Group%20N.V.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Pharming-Group-N.V.&v=1772616006881 "Chart of the company's future (projected) P/E Pharming Group N.V.")
Future (projected) P/E of the market segment - Pharma immune
Pharming Group is a biopharmaceutical company specializing in developing drugs for the treatment of rare genetic diseases. Their flagship product treats hereditary angioedema. The chart reflects average profitability expectations for the biotech sector. PHARMING Group's position relative to the benchmark demonstrates market confidence in their current product and development pipeline.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772616006912 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Pharming Group N.V. is a biopharmaceutical company developing drugs for rare diseases. Its valuation depends on the success of its drugs and their commercialization prospects. This market sentiment chart is important because during periods of optimism, investors are more inclined to fund expensive biotech research and development.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772616006923 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Pharming Group N.V.
Pharming Group N.V. is a biopharmaceutical company developing and commercializing drugs for the treatment of rare diseases, such as hereditary angioedema. The profit chart demonstrates the financial success of their flagship product, Ruconest. Sales growth directly determines the company's financial health.
Profit of companies in the market segment - Pharma immune
Pharming Group develops and commercializes innovative drugs for the treatment of rare diseases, particularly hereditary angioedema. The company's future depends on the success of its biotech developments. This chart reflects the overall profitability of its segment, demonstrating how successfully the pharmaceutical industry is commercializing therapies for orphan diseases.
Overall market profit
Pharming Group develops drugs to treat rare genetic diseases. For such companies, the key factor is not so much the current economic cycle as the availability of capital for research. However, the overall market stability, visible in this chart, influences investor sentiment and their willingness to invest in long-term, risky biotech projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Pharming Group N.V.
Pharming Group develops and commercializes drugs for the treatment of rare and orphan diseases. Its financial success depends on sales of its flagship product and progress in clinical trials of new candidates. This chart shows analyst forecasts, which assess the current commercial potential and future prospects of the company's R&D pipeline.
%20profit%20of%20the%20company%20Pharming%20Group%20N.V.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Pharming-Group-N.V.&v=1772616007077 "Graph of future (projected) profit of the company Pharming Group N.V.")
Future (predicted) profit of companies in the market segment - Pharma immune
Pharming Group develops drugs to treat rare genetic diseases, such as hereditary angioedema. The company's success depends on expanding markets for its core product and successful clinical trials of new drugs. This chart shows profitability forecasts for the pharmaceutical sector, providing context for evaluating Pharming's niche strategy.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772616007180 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Pharming Group develops drugs to treat rare diseases. Demand for such drugs is typically inelastic, as they are vital. Therefore, the company's business correlates weakly with general economic cycles, as shown in this chart. The main risks and opportunities lie in research and patents.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772616007201 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Pharming Group N.V.
Pharming Group develops and commercializes drugs for rare diseases. Its valuation, as shown in this chart, is highly dependent on the success of one or more key products. A high valuation indicates investor confidence in the potential of its blockbuster drugs and the company's ability to effectively commercialize its developments.
P/S market segment - Pharma immune
Pharming Group develops and commercializes drugs for the treatment of rare genetic diseases. The company's revenue is generated through sales of its core product. This metric reflects the average revenue estimate for biopharmaceutical companies and helps understand how the market perceives the market potential of Pharming Group's current and future drugs.
P/S of the market as a whole
Pharming Group is a biopharmaceutical company specializing in developing drugs to treat rare genetic diseases. Its main product is used to treat hereditary angioedema. This chart provides an overview of overall revenue estimates, allowing one to assess the market premium for a business focused on niche but life-saving drugs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Pharming Group N.V.
Pharming Group is a biopharmaceutical company specializing in developing drugs to treat rare genetic diseases. Its flagship product is designed to treat hereditary angioedema. This chart shows the estimated future sales of its drugs, reflecting investor confidence in the growth of rare disease diagnoses and expanding markets.
%20P%2FS%20Pharming%20Group%20N.V.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Pharming-Group-N.V.&v=1772616007374 "The graph of the company's future (projected) P/S Pharming Group N.V.")
Future (projected) P/S of the market segment - Pharma immune
Pharming Group is a biopharmaceutical company that develops and commercializes drugs for the treatment of rare genetic diseases. Its lead product treats hereditary angioedema. The company's valuation reflects sales expectations for this drug and the potential of its development pipeline in the rare disease field, where drug prices are high.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772616007446 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Pharming Group N.V. develops and commercializes drugs for the treatment of rare genetic diseases. Its success depends on demand for these highly specialized medications. In the overall revenue growth picture illustrated by the chart, Pharming represents a niche but high-margin biotech segment.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772616007571 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Pharming Group N.V.
Pharming Group is a biopharmaceutical company whose primary revenue is generated from sales of Ruconest. This medication is used to treat a rare genetic disorder, hereditary angioedema. The graph below shows the drug's sales volume in Europe and the US and efforts to expand its use.
Sales of companies in the market segment - Pharma immune
Pharming Group (PHAR) is a biopharmaceutical company specializing in developing drugs for the treatment of rare genetic diseases. Its flagship product, Ruconest, is used to treat hereditary angioedema. The graph shows the overall revenue of the pharmaceutical sector, where Pharming occupies an important niche by developing life-saving drugs for orphan diseases.
Overall market sales
Pharming Group develops drugs to treat rare genetic diseases. Its success depends on scientific innovation, but the overall economic situation, shown in this chart, plays a significant role. Economic growth facilitates stable funding for healthcare systems and ensures effective demand for expensive orphan drugs from insurers and governments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Pharming Group N.V.
Pharming Group develops and commercializes recombinant protein-based therapies for the treatment of rare diseases. The company's sales depend on the success of its flagship drug, Ruconest, and the launch of new drugs. This chart reflects analyst revenue forecasts based on market size estimates for its products and the competitive landscape in the orphan disease sector.
%20sales%20of%20the%20company%20Pharming%20Group%20N.V.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Pharming-Group-N.V.&v=1772616007927 "Schedule of future (projected) sales of the company Pharming Group N.V.")
Future (projected) sales of companies in the market segment - Pharma immune
Pharming Group is a biopharmaceutical company developing drugs for rare diseases. This chart details projected sales of their lead product, Ruconest, for the treatment of hereditary angioedema. It provides insight into analysts' perceptions of the market potential of this drug and the prospects for the company's other developments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772616007979 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Pharming Group is a biopharmaceutical company specializing in developing drugs for the treatment of rare genetic diseases. The company's success depends on sales of its commercial products and research results. This graph, reflecting the overall economic situation, influences the pricing of orphan drug treatments and healthcare budgets.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772616008031 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Pharming Group N.V.
Pharming Group is a biopharmaceutical company specializing in developing treatments for rare genetic diseases. Its profitability is directly dependent on sales of its flagship product, Ruconest, and the success of its new developments. The chart shows how the company, by focusing on a narrow but highly profitable niche, converts its scientific achievements into net profit.
Market segment marginality - Pharma immune
Pharming Group is a biopharmaceutical company specializing in developing drugs for rare diseases. Its key product is Ruconest, a treatment for hereditary angioedema. This chart shows the company's commercial profitability. Success depends on sales volumes and the expansion of its use.
Market marginality as a whole
Pharming Group develops drugs for the treatment of rare genetic diseases. The prices of these medications are very high, and their coverage depends on the capabilities of insurance systems. This overall economic profitability chart serves as a benchmark for assessing the solvency of these systems. Stable economic profitability allows for the funding of expensive therapies.
Employees in the company, segment and market as a whole
Number of employees in the company Pharming Group N.V.
Pharming Group is a biopharmaceutical company specializing in rare diseases. Its staff includes researchers, manufacturing, and sales specialists. The team's growth is directly tied to the commercial success of existing drugs and the advancement of new candidates through clinical development in various countries.
Share of the company's employees Pharming Group N.V. within the market segment - Pharma immune
Pharming Group develops and manufactures innovative protein therapeutics for rare diseases. In this highly specialized pharmaceutical segment, its scientific and manufacturing staff are key assets. This chart shows the human capital the company invests in creating and delivering life-saving medications for small patient populations.
Number of employees in the market segment - Pharma immune
Pharming Group develops drugs to treat rare genetic diseases. The employment dynamics in immunological pharmacology, shown in the graph, illustrate the intensity of research in this complex field. For Pharming, the growing number of scientists means both accelerating discovery and the need to compete for the best scientific talent to advance its unique drugs.
Number of employees in the market as a whole
Pharming Group is a biopharmaceutical company specializing in rare diseases. Its highly specialized staff grows based on scientific breakthroughs and product approvals, making it less susceptible to general economic fluctuations. It recruits elite talent from a global marketplace, reflected in these common metrics.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Pharming Group N.V. (PHAR)
Pharming Group is a biopharmaceutical company specializing in drugs for the treatment of rare genetic diseases. Its flagship product, Ruconest, is produced using transgenic rabbits. This chart shows how the market values its unique technology platform and portfolio of orphan drug products, which generates high employee value.
%20of%20the%20company%20Pharming%20Group%20N.V.%20(PHAR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Pharming-Group-N.V.-PHAR&v=1772616008291 "Chart of market capitalization per employee (in thousands of dollars) of the company Pharming Group N.V. (PHAR)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Pharming Group develops drugs for the treatment of rare diseases. In this pharmaceutical segment, value is determined by the uniqueness and patent protection of one or more products. This metric demonstrates the enormous value the market places on a company's intellectual property, given its relatively small staff.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772616008304 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Pharming Group develops and commercializes drugs for rare diseases. The chart shows the valuation of a biotech company with a commercialized product. The high cost per employee reflects the high margins of orphan drugs, as well as the value of ongoing research and development by its team of scientists.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772616008325 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Pharming Group N.V. (PHAR)
Pharming Group is a biotech company that develops and markets drugs for rare diseases (such as Ruconest). Their business is R&D and marketing of highly specialized, expensive drugs. This chart shows how effectively their small team (scientists and marketers) generates profit from the sale of high-margin orphan drugs.
%20Chart%20Pharming%20Group%20N.V.%20(PHAR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Pharming-Group-N.V.-PHAR&v=1772616008342 "Company Profit Per Employee (in thousands of dollars) Chart Pharming Group N.V. (PHAR)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Pharming Group is a biopharmaceutical company that develops and markets drugs for the treatment of rare (orphan) diseases. Their key product is Ruconest. Earnings per employee in this sector can be very high, as successful drugs for rare diseases are highly priced and protected by patents.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772616008375 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Pharming Group is a biopharmaceutical company developing drugs for the treatment of rare (orphan) diseases. Their key product treats hereditary angioedema. In this business, high profits per employee are achieved through the scientific uniqueness of the product and its extremely high price, which is due to the complexity of development and the small patient market. This chart illustrates the economics of "ultra-orphan" drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772616008434 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Pharming Group N.V. (PHAR)
Pharming Group develops and markets drugs to treat rare genetic diseases, such as hereditary angioedema. This biopharmaceutical company's revenue per employee reflects the commercial success of its flagship product. The chart shows the sales growth of this life-saving drug in global markets.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Pharming-Group-N.V.-PHAR&v=1772616008436 "Sales chart per company employee Pharming Group N.V. (PHAR)")
Sales per employee in the market segment - Pharma immune
Pharming Group (PHAR) is a biopharmaceutical company specializing in developing treatments for rare diseases, specifically hereditary angioedema. This chart shows the average revenue per employee in this segment. It helps assess how effectively Pharming generates sales for its drugs using its team.
Sales per employee for the market as a whole
Pharming Group (PHAR) is a biotech company specializing in rare (orphan) diseases. Their key product is a treatment for hereditary angioedema. For a biotech with an approved product, this metric demonstrates commercial effectiveness. It shows how much sales volume for a high-margin drug is generated by the company's team, including manufacturing and a dedicated sales department.
Short shares by company, segment and market as a whole
Shares shorted by company Pharming Group N.V. (PHAR)
Pharming Group (PHAR) is a biotech company specializing in rare (orphan) diseases. Its key product is a treatment for hereditary angioedema. This chart measures bearish sentiment. The rise in bearish bets may be related to concerns about the emergence of competing treatments or challenges in expanding the company's product portfolio beyond a single blockbuster. (347)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Pharming-Group-N.V.-PHAR&v=1772616008612 "Short Shares Chart for the Company Pharming Group N.V. (PHAR)")
Shares shorted by market segment - Pharma immune
Pharming Group is a Dutch biotech company whose main product (Ruconest) treats a rare genetic disease (hereditary angioedema). This chart shows the overall sentiment in the sector, reflecting investor concerns about competition or companies' reliance on a single drug.
Shares shorted by the overall market
Pharming Group specializes in treating rare diseases. It's a seemingly protected sector—patients can't refuse medications. However, this indicator of general fear suggests that investors are selling everything in a panic. They may fear price pressure from governments, which are seeking ways to cut costs on expensive drugs during the recession.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Pharming Group N.V. (PHAR)
Pharming Group (PHAR) is a biopharmaceutical company specializing in rare diseases. Their main product is Ruconest, a treatment for hereditary angioedema (HAE). This chart measures hype. It shows "overbought" (above 70) on strong sales data or R&D successes, and "oversold" (below 30) on news about competitive threats.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Pharming-Group-N.V.-PHAR&v=1772616008737 "RSI 14 indicator chart for the company's stock Pharming Group N.V. (PHAR)")
RSI 14 Market Segment - Pharma immune
Pharming Group (PHAR) is a biopharmaceutical company specializing in the treatment of rare diseases, particularly hereditary angioedema. This chart tracks the overall sentiment in the Pharma/Immunology sector. It helps investors understand whether PHAR's performance reflects its pipeline or whether the entire biotech sector is overheated or oversold.
RSI 14 for the overall market
Pharming Group (PHAR) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PHAR (Pharming Group N.V.)
Pharming Group is a biopharmaceutical company specializing in rare diseases. Its key product, Ruconest, is used to treat hereditary angioedema. This chart shows the analyst consensus: their average price target for PHARMING Group shares.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PHAR-Pharming-Group-N.V.&v=1772616008839 "A chart showing analyst consensus forecasts for the expected stock price. PHAR (Pharming Group N.V.)")
The difference between the consensus estimate and the actual stock price PHAR (Pharming Group N.V.)
Pharming Group is a Dutch biopharmaceutical company. Their main commercial product is Ruconest, a treatment for the rare disease HAE (hereditary angioedema). This chart shows how analysts assess the commercial success of this drug and their R&D pipeline for other rare diseases.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PHAR-Pharming-Group-N.V.&v=1772616008864 "A chart showing the difference between the consensus forecast and the actual stock price. PHAR (Pharming Group N.V.)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Pharming Group is a Dutch biopharmaceutical company whose flagship product, Ruconest (derived from the milk of transgenic rabbits), treats the rare disease hereditary angioedema. This chart shows general expectations for the immunopharma sector, reflecting whether experts believe the rare disease market will grow.
Analysts' consensus forecast for the overall market share price
Pharming Group N.V. is a Dutch biopharmaceutical company specializing in rare diseases. Their key product is a treatment for hereditary angioedema. This chart shows overall market sentiment. For Pharming, whose success depends on sales of a niche drug, overall optimism is important for supporting its valuation, but their business is considered relatively defensive.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Pharming Group N.V.
Pharming Group is a European biotech company focused on rare (orphan) diseases. Their commercial success is built on a single drug, Ruconest, which is used to treat hereditary angioedema (HAE). This chart evaluates their single-product model. It measures the stability of Ruconest sales and market confidence in their R&D pipeline.
AKIMA Market Segment Index - Pharma immune
Pharming Group (PHAR) is a Dutch biotech focused on rare diseases; the company owns the commercial drug Ruconest (for the treatment of HAE) and is developing new therapies. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this niche (HAE) model (PHAR) differentiate it from the average pharma company?
The AKIM Index for the overall market
Pharming Group is a biopharmaceutical company specializing in human proteins for the treatment of rare genetic diseases (angioedema). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this European company with commercial products compares to overall economic trends and currency risks.
